India drugmaker News

In Mumbai trading so far this year, Lupin Ltd has climbed 32 percent, Dr. Reddy`s 31 percent, Glenmark Pharmaceuticals 42 percent and Wockhardt 29 percent.

India's largest drugmaker Sun Pharma may file application for a new drug with the US Food and Drug Administration in next two to three years, the company's Managing Director Dilip Shanghvi said on Thursday.

Shares in Sun Pharmaceutical Industries slumped 16 percent, heading towards their biggest daily fall ever, after the drugmaker on Monday said it sees 2016 sales flat at best.

Shares of drugmaker Lupin rose by almost 2 percent after the stock became part of the BSE benchmark Sensex from on Monday.

Drug major Sun Pharma on Saturday reported 6.92 percent decline in consolidated net profit at Rs 1,425.07 crore for the third quarter ended December 31, 2014-15, saying it was hit by supply constraints.

Dr Reddy's Laboratories on Friday said the Bombay High Court has granted an interim stay on an order issued by the Maharashtra drug controller (FDA) for a one-month suspension of wholesale licence of the company's clearing and forwarding agent in Bhiwandi near Thane.

Lupin Ltd , India`s fourth-largest drugmaker by sales, reported a higher-than-expected profit in the first quarter, helped mainly by higher sales in the United States and India, and lower expenses.